Clinical Trials Logo

Healthy Adults clinical trials

View clinical trials related to Healthy Adults.

Filter by:

NCT ID: NCT06315517 Not yet recruiting - Healthy Adults Clinical Trials

Double Crossover Casein Type Tolerance Trial

Start date: April 2024
Phase: N/A
Study type: Interventional

The investigators will recruit 45 fluid milk avoiding adults to participate in a five-week double-blind, double-crossover study in which the physiological responses to increasing doses of lactose-free (A1-rich milk), A2 milk, and lactose-free A2 milk will be explored.

NCT ID: NCT06312930 Not yet recruiting - Healthy Adults Clinical Trials

Transcranial Pulse Stimulation on Motor Cortex

Start date: March 20, 2024
Phase: N/A
Study type: Interventional

Transcranial pulse stimulation (TPS) is a newly developed non-invasive brain stimulation (NIBS) technique from Austria & Germany with highly promising applicability in neuropsychiatric disorders. Clinical trials have shown a beneficial effect of TPS in patients with Alzheimer's disease and depression. However, the mechanism of action of TPS treatment is unknown. There is a lack of controlled studies with sufficient sample size to draw reliable conclusions on the modulatory effect of TPS. The primary motor cortex is a common target when investigating the neuromodulation effect of NIBS techniques. Here, a randomized, cross-over, double-blind, sham-controlled clinical trial is proposed to probe the effects of TPS over the primary motor cortex on modulating motor response and motor behavior.

NCT ID: NCT06272747 Not yet recruiting - Healthy Adults Clinical Trials

A Phase I Study of XH-S003 in Healthy Volunteers

Start date: February 22, 2024
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S003 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S003.

NCT ID: NCT06259825 Recruiting - Healthy Adults Clinical Trials

Omega-3-Index Response to Eating Poultry Foods Naturally Enriched With Omega-3 Polyunsaturated Fatty Acids

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

Diets low in seafood omega-3 polyunsaturated fatty acids (PUFAs) are very prevalent. Such diets have recently been ranked as the sixth most important dietary risk factor-1.5 million deaths and 33 million disability-adjusted life-years worldwide are attributable to this deficiency. Wild oily fish stocks are insufficient to feed the world's population, and levels of eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) in farmed fish have more than halved in the last 20 years. The primary objective of this randomised, double-blinded, controlled nutritional trial will be to test if consumption of at least 4 servings of omega-3 PUFA-enriched chicken-meat and 4 enriched eggs per week, over a 4-month period, results in measurably higher blood levels of EPA and DHA in healthy Saudi adults. This will be a randomised double-blind interventional study. Eighty adult male and female participants (age ≥ 18 years of age) will be asked to eat at least 4 portions of omega-3-PUFA enriched (or control) chicken-meat per week, and at least 4 omega-3-PUFA enriched (or control) eggs per week, for 4 months. Participants will be assessed at baseline and at monthly intervals for 4 months. Assessments at these visits will include; comprehensive lifestyle and medical history; food frequency questionnaire; 3 days food record; height, weight, waist and hip circumferences; blood sampling; participant well-being and adverse events. Measurement of plasma and red blood cell levels of EPA, DHA and Docosapentaenoic acid (DPA) will be performed at baseline and at study end using gas chromatography-mass spectroscopy. The primary end point will be the change in red blood cell omega-3-index (sum of EPA and DHA expressed as percentage of total fatty acids in erythrocyte membranes) at 4 months. The nutritional trial will be analyzed on an intension to treat basis. Repeated measures ANOVA will be used to compare the two study groups. The study will be reported in accordance with the CONSORT (Consolidated Standards of Reporting Trials) 2010 statement.

NCT ID: NCT06245538 Not yet recruiting - Healthy Adults Clinical Trials

Exercise Intensity on Brain & Mental Health in Stress

ExStress
Start date: February 2024
Phase: N/A
Study type: Interventional

This study aims to examine the role of exercise intensity in the acute effects of a single bout of aerobic exercise on neurotrophic factors, biomarkers of stress and inflammation, working memory task-related changes in prefrontal cortex oxygenation in adults with stress-related symptoms, and matched healthy controls.

NCT ID: NCT06236841 Not yet recruiting - Healthy Adults Clinical Trials

A Phase I Study of XH-S004 in Healthy Volunteers

Start date: January 26, 2024
Phase: Phase 1
Study type: Interventional

This is a phase I, randomised, double-blind placebo-controlled, 3-part study to assess the safety, tolerability, pharmacokinetics and food effect of single and multiple oral doses of XH-S004 in healthy volunteers.

NCT ID: NCT06227832 Recruiting - Healthy Adults Clinical Trials

A Study to Determine the Effect of KP-001 on Metformin and Midazolam Pharmacokinetics and the Effect of Clarithromycin on KP-001 Pharmacokinetics in Healthy Adult Participants

Start date: December 15, 2023
Phase: Phase 1
Study type: Interventional

The purpose of this study is to determine the Effects of KP-001 on Metformin (a substrate of MATE1) and Midazolam (a substrate of CYP3A4) Pharmacokinetics and the Effect of Clarithromycin (potent CYP3A4/P-gp Inhibitor) on KP-001 Pharmacokinetics in Healthy Adult Participants. The study will also evaluate the safety and tolerability of KP-001 with and without a single dose or multiple doses of an interaction drug. The study comprises 3 parts. Participants will stay in the Clinical Unit during the study, depending on which part they assigned to. Participants will remain at the clinical site for a 13 day/12 night in-house stay (Part 1), a 14 day/13 night in house stay (Part 2), or a 11 day/10 night in-house stay (Part 3).

NCT ID: NCT06204419 Recruiting - Healthy Adults Clinical Trials

A Phase I Study of XH-S002 in Healthy Volunteers

Start date: December 26, 2023
Phase: Phase 1
Study type: Interventional

The purpose of the study is to assess the safety, tolerability and pharmacokinetics of XH-S002 in healthy volunteers under SAD (Single ascending dose) and MAD (Multiple ascending dose) studies. In addition, this study evaluates the food effects of XH-S002.

NCT ID: NCT06167382 Completed - Healthy Adults Clinical Trials

The Effect of Arm Ergometer Exercise on Dexterity

Start date: December 25, 2022
Phase: N/A
Study type: Interventional

The goal of this single group assessment study is to investigate acute effect of arm ergometer exercise intensity on dexterity and hand reaction time in healthy male or female participants aged 18-35. - Knowing the acute effect and change of hand dexterity and reaction times of individuals with arm ergometer intensities applied at different intensities provides us with data that can be processed and used in neurological, orthopedic patient groups and geriatric cases during the rehabilitation process. - The positive gains enable us to obtain effective and observable results in the rehabilitation progression of individuals and in parameters such as muscle strength and endurance, quality of life, depression, chronic pain. Participants who accepted the voluntary basis will be taken and the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) will be filled. After all evaluations were made to the participants, 3 different exercise intensities; maximum heart rates; 60%, 70%, 80% will do arm ergometer exercises. - ROM measurements - Muscle strength tests - Grip strength measurement (Jamar hand dynamometer) - Dexterity and Function tests (Nelson Hand Reaction Test - Purdue Pegboard Test - Minnesota Manual Dexterity Test) evaluation parameters will be applied before, immediately after and 15 minutes after each exercise intervention.

NCT ID: NCT06133530 Enrolling by invitation - Healthy Adults Clinical Trials

Human Milk Oligosaccharides (HMOs) and Gut Microbiota, Immune System in Antarctica

Start date: September 24, 2023
Phase: N/A
Study type: Interventional

Human milk oligosaccharides (HMOs) are the third-most abundant component in mothers' milk and are an important prebiotic factor for the development of the gut microbiota of infants, promoting the growth of certain beneficial bacterial strains and providing protection against many bacterial and viral infections. HMOs induce immunomodulatory activity by affecting immune cell populations and functions. In a simulator of the adult human intestinal microbial ecosystem, fermentation of HMOs led to an increase of bifidobacteria in parallel with an increase in short-chain fatty acids as well as a reduction in inflammation markers, supporting the potential of HMOs to provide health benefits also in adults. Long-term stay in microgravity induces many physiological responses, including diminished immune function and impaired glucose tolerance which may lead to rather severe consequences. Similarly, hypoxia conditions as in the Concordia station, affects the immune system and may lead to impaired glucose tolerance and insulin resistance. The hypothesis is that HMOs as a prebiotic supplement will mitigate changes in immune function, glucose tolerance, lipid homeostasis, and neurotransmitter production. It is expected that HMO supplementation will - Modulate gut microbiota composition and function - Improve inflammation status - Improve immune function - Improve glucose tolerance - Improve nutritional status - Prevent changes in neurotransmitters associated with anxiety and depression. During the stay in Antarctica an HMO blend will be supplemented to the verum group of volunteers. The control group will receive a placebo. Experiment days with blood drawing, an oral glucose tolerance test, saliva sampling, and feces samples are planned once before, about every second month in Concordia, and once after return.